NEW YORK, NY / ACCESSWIRE / May 29, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (ADMS). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/adms.
The investigation concerns whether Adamasand certain of its officers and/or directors have issued materially misleading business information to the investing public.
In January 2018 Adamas completed its Second Public Offering ("SPO") at $41.50 per share. It is alleged that Adamas knew it had considerable roadblocks that would decrease its ability to sell Gocovri, its new medicine used to treat dyskinesia in Parkinson's disease patients treated with levodopa therapy. The investigation also alleges that company failed to reveal these issues in its SPO and consequently, misled investors. Later in October 2018, Merrill Lynch published a report pointing to serious doubt on Adamas and Gocovri's chance on the market. In March 2019, Adamas released updated projections well below previous expectations. As a result, Adamas stock dropped below the SPO price.
If you are aware of any facts relating to this investigation, or purchased shares of Adamas, you can assist this investigation by visiting the firm's site: www.bgandg.com/adms. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com: